Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 7/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | CDC25C | P30307 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353275 | 0.88 | NQO1 (0.51) | NQO1CDC25ACDC25CPRNPRXFP1 | |
| SCHEMBL5342546 | 0.87 | NQO1 (0.49) | NQO1PRNPRXFP1HSD17B3ESR1 | |
| SCHEMBL5337199 | 0.85 | NQO1 (0.39) | NQO1CDC25ACDC25CPRNPRXFP1 | |
| SCHEMBL5337846 | 0.85 | NQO1 (0.39) | NQO1CDC25ACDC25CPRNPRXFP1 | |
| SCHEMBL5344414 | 0.82 | NQO1 (0.37) | NQO1PRNPRXFP1HSD17B3 | |
| SCHEMBL5342077 | 0.82 | NQO1 (0.54) | NQO1TP53NPC1RAB9A | |
| SCHEMBL5352117 | 0.82 | NQO1 (0.53) | NQO1PRNPRXFP1TP53 | |
| SCHEMBL5338112 | 0.78 | NQO1 (0.38) | NQO1PRNPRXFP1NPC1RAB9A | |
| SCHEMBL5344388 | 0.77 | PRNP (0.45) | NQO1PRNPRXFP1HSD17B3TP53 | |
| SCHEMBL5341857 | 0.77 | NQO1 (0.49) | NQO1PRNPRXFP1HSD17B3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | claimed |
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | claimed |
| EP-1648901-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-04-26 | — | — | EP | claimed |
| WO-2005010006-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-02-03 | — | — | WO | claimed |
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | LTC4S, CYP11B2, CYP11B1 | NQO1 91/4885CDC25A 3955/4885CDC25C 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.